
US-based BioTheryX: Developing therapies for hematological malignancies.
Founded in Chappaqua, United States, BioTheryX is a clinical-stage biopharmaceutical company dedicated to developing therapies for hematological malignancies and other serious diseases. The company’s core mission is to advance medical treatments through innovative science, specifically focusing on the development of first-in-class protein degraders. Utilizing their proprietary PRODEGY platform, BioTheryX aims to target and degrade disease-causing proteins, with an initial emphasis on cancer and inflammatory diseases.
BioTheryX has garnered attention for its pioneering work in targeted protein degradation. The company boasts a team of experienced leaders in biopharmaceutical innovation and has attracted significant interest from investors in the healthcare sector. Notable achievements include the successful advancement of their drug candidates into clinical trials, demonstrating potential efficacy in treating complex diseases. Overall, BioTheryX is making a substantial impact by pushing the boundaries of traditional drug discovery and offering new hope for patients with challenging conditions.

76Bio
76bio.com

Kymera Therapeutics
kymeratx.com

Therapyx
therapyxinc.com

Nurix
nurixtx.com

EpiBiologics
epibiologics.com

Arvinas
arvinas.com

ProThera Biologics

Juvena Therapeutics

C4 Therapeutics
c4therapeutics.com

Neomorph
neomorph.com

Biora Therapeutics

Plexium
plexium.com

Pharmatrophix
pharmatrophix.com

BioXyTran
bioxytraninc.com

CytomX Therapeutics
cytomx.com
Companies similar to Biotheryx include 76Bio, Kymera Therapeutics, Therapyx and Nurix.
Biotheryx was founded in 2007.
Biotheryx's headquarters is located in San Diego, CA, US.
Biotheryx's most recent funding round was for $6M (USD) in April 2023.
As of Apr 5, 2023, Biotheryx has raised a total of $134.7M (USD).
Biotheryx has 39 employees as of Feb 5, 2024.